Literature DB >> 9061581

Inhibition and interaction of cytochrome P450 of Candida krusei with azole antifungal drugs.

K Venkateswarlu1, D W Denning, S L Kelly.   

Abstract

Candida krusei has become an increasingly important invasive pathogen, particularly in AIDS patients and is highly resistant to fluconazole. In vitro growth inhibition studies revealed that fluconazole and ketoconazole were approximately 800- and 19-fold less inhibitory than itraconazole. The inhibition and interaction of itraconazole, fluconazole and ketoconazole with the sterol 14 alpha-demethylase of C. krusei was studied using in vitro ergosterol biosynthesis and difference spectroscopy, respectively. Both itraconazole and ketoconazole inhibited in vitro ergosterol biosynthesis at lower concentrations than fluconazole. All three drugs interacted with microsomal P450 and interfered in the binding of carbon monoxide to P450 in direct proportion to their inhibitory effect on ergosterol biosynthesis in cell-free extracts. The slightly lower affinity of sterol 14 alpha-demethylase for fluconazole compared with itraconazole and ketoconazole is only partially responsible for poor activity of fluconazole on C. krusei.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9061581

Source DB:  PubMed          Journal:  J Med Vet Mycol        ISSN: 0268-1218


  14 in total

1.  Arv1 lipid transporter function is conserved between pathogenic and nonpathogenic fungi.

Authors:  Christina Gallo-Ebert; Paula C McCourt; Melissa Donigan; Michelle L Villasmil; WeiWei Chen; Devanshi Pandya; Judith Franco; Desiree Romano; Sean G Chadwick; Scott E Gygax; Joseph T Nickels
Journal:  Fungal Genet Biol       Date:  2011-11-27       Impact factor: 3.495

Review 2.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

Review 3.  Azole resistance in Candida.

Authors:  D W Denning; G G Baily; S V Hood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

4.  The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents.

Authors:  D Sanglard; F Ischer; D Calabrese; P A Majcherczyk; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

5.  Fungicidal activity of thymol and carvacrol by disrupting ergosterol biosynthesis and membrane integrity against Candida.

Authors:  A Ahmad; A Khan; F Akhtar; S Yousuf; I Xess; L A Khan; N Manzoor
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-11       Impact factor: 3.267

6.  Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei.

Authors:  Chiatogu Onyewu; Jill R Blankenship; Maurizio Del Poeta; Joseph Heitman
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

7.  Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.

Authors:  Erwin Lamping; Amrita Ranchod; Kenjirou Nakamura; Joel D A Tyndall; Kyoko Niimi; Ann R Holmes; Masakazu Niimi; Richard D Cannon
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

Review 8.  Efflux-mediated antifungal drug resistance.

Authors:  Richard D Cannon; Erwin Lamping; Ann R Holmes; Kyoko Niimi; Philippe V Baret; Mikhail V Keniya; Koichi Tanabe; Masakazu Niimi; Andre Goffeau; Brian C Monk
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

9.  Mechanism of fluconazole resistance in Candida krusei.

Authors:  A S Orozco; L M Higginbotham; C A Hitchcock; T Parkinson; D Falconer; A S Ibrahim; M A Ghannoum; S G Filler
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

10.  Upregulation of the ERG11 gene in Candida krusei by azoles.

Authors:  M Tavakoli; F Zaini; M Kordbacheh; M Safara; R Raoofian; M Heidari
Journal:  Daru       Date:  2010       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.